Dalfampridine Tablet, Film Coated, Extended Release
Product Images NDC 82249-702

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Dalfampridine (NDC 82249-702). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Civicascript Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dalfampridine (Dalfampridine Con 1)

Label for Dalfampridine extended-release tablets, 10 mg, with a 60 tablet count. The label includes storage instructions, dosage note, and pharmacist dispensing guidance. Distributed by CivicaScript LLC and manufactured by Alkem Laboratories Ltd. Location details for both companies are listed. There is a QR code for additional product information and a barcode with the product NDC 82249-702-60.*

FDA Label Image

Dalfampridine-equa (Dalfampridine Equa)

An illustration showing a formula calculation for creatinine clearance (Crcl). The formula is written as ((140 - age) x weight in kilograms) divided by (Serum creatinine in mg/dL times 72). This mathematical expression is used to estimate kidney function.*

FDA Label Image

Dalfampridine-fig1 (Dalfampridine Fig1)

A bar chart comparing the percentage of patients achieving various average percent increases in walking speed from baseline between placebo and Dalfampridine extended-release tablets 10 mg b.i.d. The x-axis shows thresholds of walking speed improvement (≥0% to ≥60%), and the y-axis shows the percentage of patients. Data series include placebo (N=72) and Dalfampridine 10 mg extended-release (N=224).*

FDA Label Image

Dalfampridine-fig2 (Dalfampridine Fig2)

A bar chart comparing the percentage of patients achieving various thresholds of average percent increase in walking speed from baseline between placebo and Dalfampridine Extended-release Tablets 10 mg twice daily groups. The x-axis shows walking speed increase thresholds (≥0%, ≥10%, ≥20%, ≥30%, ≥40%, ≥50%, ≥60%). The y-axis shows the percentage of patients. Bars for the Dalfampridine group are higher at almost all thresholds compared to placebo.*

FDA Label Image

Dalfampridine-struc (Dalfampridine Struc)

Chemical structure of Dalfampridine, showing a six-membered aromatic ring with one nitrogen atom and an attached amino group (NH2).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.